statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 PR Newswire VANCOUVER, BC, May 1, 2024 USA News Group Commentary...

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data...

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate

Latest Ratings for MGNX
 DateFirmActionFromTo Feb 2022CitigroupUpgradesNeutralBuy Feb 2022SVB LeerinkMaintainsOutperform Feb 2022BMO CapitalInitiates Coverage OnOutperform
 View More Analyst...

The Latest Analyst Ratings For Macrogenics

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MacroGenics shares volatile post update on Tamarack and upcoming ASCO meeting

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data...

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) fell 3.6% on Thursday . The stock traded as low as $14.40 and last traded at $14.42. 30,770 shares traded hands during mid-day trading, a decline of...

MacroGenics (NASDAQ:MGNX) Stock Price Down 3.6%

Wellington Management Group LLP grew its position in MacroGenics, Inc. (NASDAQ:MGNX  Free Report) by 3.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund...

Wellington Management Group LLP Increases Stake in MacroGenics, Inc. (NASDAQ:MGNX)

This is a signal that MGNX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

MacroGenics (MGNX, $14.98) RSI Indicator left the oversold zone on March 27, 2024

MacroGenics (MGNX, $14.48) RSI Indicator left the oversold zone on March 22, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

MacroGenics (MGNX, $15.4) price exceeded its 50-day Moving Average on March 20, 2024

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Volume	620,486.00
52-Wk High	$21.88
52-Wk Low	$4.29

MGNX Macrogenics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals